代谢综合征相关的勃起功能障碍:多种血管内皮功能障碍机制和潜在的治疗点
Hao Wang1, Jun Guo1,2, Eric Chung3,4
1Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
International journal of biological sciences
|October 13, 2025
概括
代谢综合征 (MetS) 通过损害阴茎血管内皮,导致勃起功能障碍 (ED). 了解这些机制,包括胰岛素抵抗和高血压,是开发新ED治疗的关键.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 代谢综合征 (MetS) 通过血管和神经损伤与勃起功能障碍 (ED) 有关.
- 阴茎血管内皮功能障碍是MetS相关性ED的一个关键特征.
- MetS通过胰岛素耐药性,失脂症,高血压和肥胖症加剧ED.
研究的目的:
- 审查阴茎血管内皮功能障碍在MetS相关ED的机制.
- 讨论MetS成分对阴茎血管内皮的影响.
- 探索MetS相关ED的潜在治疗点.
主要方法:
- 对MetS和ED研究的文献综述.
- 分析将MetS组件与阴茎血管功能障碍联系起来的病理机制.
- 综合当前对治疗策略的理解.
主要成果:
- MetS通过协同效应损害阴茎洞腔血管功能.
- 病理过程包括血管扩张受损,纤维化和血液流量减少.
- 葡萄糖代谢障碍,高血压,脂质障碍和肥胖症都起着重要的作用.
结论:
- 阴茎血管内皮功能障碍是MetS相关的ED的核心.
- 准MetS组件为ED提供了治疗潜力.
- 进一步的研究可以确定MetS相关ED患者的新型治疗策略.
相关概念视频
Disorders of the Male Reproductive System
4.0K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
4.0K
Coronary Artery Disease I: Introduction
878
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
878
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
557
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
557
Coronary Artery Disease II: Pathophysiology
367
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
367
Hypertension II: Pathophysiology
787
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
787
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319


